Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).
Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).
In May 2014, the FDA approved home administration of the subcutaneous injection for patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to treatment with tyrosine-kinase inhibitors (TKIs).
Prior to the approval, patients had to travel to the clinic to receive their injections, which Kropf says was burdensome and inconvenient. The injections can be administered by the patients or caregivers.
Kropf adds that she anticipates seeing an expansion of Synribo prescriptions because of the approval.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.